{"doc_id": "si-2024-0582-reg-1", "parent_doc_id": "si-2024-0582", "section_id": "reg-1", "section_label": "Regulation 1.", "si_number": "S.I. No. 582 of 2024", "title": "“Principal Regulations” means the Medicinal Products (Prescription and Control", "year": 2024, "heading": "1. (1) These Regulations may be cited as the Medicinal Products", "text_raw": "1. (1) These Regulations may be cited as the Medicinal Products \n\n(Prescription and Control of Supply) (Amendment) (No. 5) Regulations 2024. \n\n(2) The collective citation “the Medicinal Products (Prescription and Control \n\nof Supply) Regulations 2003 to 2024” includes these Regulations.", "text_norm": "1 (1) regulation may cited medicinal product (prescription control supply) (amendment) (no 5) regulation 2024 (2) collective citation medicinal product (prescription control supply) regulation 2003 2024 includes regulation", "start_char": 622, "end_char": 912, "source_path": "downloads\\2024\\2024_0582.pdf", "extraction_method": "pdfminer", "checksum": "sha256:605b5ae642fcf12b88545bd011e9e8f0d8c15091776cc2676d2f3b077c2348ea", "cross_refs": []}
{"doc_id": "si-2024-0582-reg-2", "parent_doc_id": "si-2024-0582", "section_id": "reg-2", "section_label": "Regulation 2.", "si_number": "S.I. No. 582 of 2024", "title": "“Principal Regulations” means the Medicinal Products (Prescription and Control", "year": 2024, "heading": "2. These Regulations shall come into operation on 31st October 2024.", "text_raw": "2. These Regulations shall come into operation on 31st October 2024.", "text_norm": "2 regulation shall come operation 31st october 2024", "start_char": 912, "end_char": 983, "source_path": "downloads\\2024\\2024_0582.pdf", "extraction_method": "pdfminer", "checksum": "sha256:605b5ae642fcf12b88545bd011e9e8f0d8c15091776cc2676d2f3b077c2348ea", "cross_refs": []}
{"doc_id": "si-2024-0582-reg-3", "parent_doc_id": "si-2024-0582", "section_id": "reg-3", "section_label": "Regulation 3.", "si_number": "S.I. No. 582 of 2024", "title": "“Principal Regulations” means the Medicinal Products (Prescription and Control", "year": 2024, "heading": "In these Regulations –", "text_raw": "3. \n\nIn these Regulations – \n\n“Principal Regulations” means the Medicinal Products (Prescription and Control \nof Supply) Regulations 2003 ( S.I. No. 540 of 2003); \n\n“Regulations of 2024” means the Medicinal Products (Prescription and Control \nof Supply) (No. 4) Regulations 2024 (S.I. No. 458 of 2024). \n\nThe Eighth Schedule (as amended by Regulation 7 of the 2024 Regulations) to \nthe Principal Regulations is amended by inserting the following entry: \n\nNotice of the making of this Statutory Instrument was published in \n\"Iris Oifigiúil\" of 1st November, 2024. \n\n \n \n \n \n \n \n \n \n \n\f[582] 3 \n\n“ \n\nMedicinal \nproduct \n\nRoute of \nadministration \n\nForm and \npresentation \nof the \nproduct \nadministered \n\nIndication \nfor which \nthe \nmedicinal \nproduct \nmay be \nadminister\ned \n\nDosage and \nconditions of \nadministration \n\nPlace of \nadministration \n\nColumn 1 \n\nColumn 2 \n\nColumn 3 \n\nColumn 4 \n\nColumn 5 \n\nColumn 6 \n\nDispersion for \ninjection \n\nIntramuscular \ninjection \n\nComirnaty KP.2 \n30 \nmicrograms/dose \ndispersion for \ninjection \nCOVID-19 \nmRNA Vaccine \n\nDispersion for \ninjection \n\nIntramuscular \ninjection \n\nComirnaty KP.2 \n10 \nmicrograms/dose \ndispersion for \ninjection \nCOVID-19 \nmRNA Vaccine \n\nConcentrate \nfor dispersion \nfor injection \n\nIntramuscular \ninjection \n\nComirnaty KP.23 \nmicrograms/dose \nconcentrate for \ndispersion \nCOVID-19 \nmRNA Vaccine \n\nIndicated \nfor active \nimmunisati\non to \nprevent \nCOVID-19 \ncaused by \nSARSCoV-2, in \nindividuals \n12 years of \nage and \nolder \n\nIndicated \nfor active \nimmunisati\non to \nprevent \nCOVID-19 \ncaused by \nSARSCoV-2, in \nchildren \naged 5 to \n11 years. \n\nIn accordance \nwith the summary \nof product \ncharacteristics and \nthe relevant \nrecommendations \nor guidelines \nissued by the \nNational \nImmunisation \nAdvisory \nCommittee and \naccepted by the \nMinister for \nHealth. \n\nAny suitable \nand appropriate \nplace, having \nregard to public \nconvenience \nand the need to \nprotect the \nhealth and \nsafety of the \npublic and \nsafely \nadminister the \nproduct. \n\nIn accordance \nwith the summary \nof product \ncharacteristics and \nthe relevant \nrecommendations \nor guidelines \nissued by the \nNational \nImmunisation \nAdvisory \nCommittee and \naccepted by the \nMinister for \nHealth. \n\nAny suitable \nand appropriate \nplace, having \nregard to public \nconvenience \nand the need to \nprotect the \nhealth and \nsafety of the \npublic and \nsafely \nadminister the \nproduct. \n\nIndicated \nfor active \nimmunisati\non to \nprevent \nCOVID-19 \ncaused by \nSARSCoV-2, in \ninfants and \nchildren \naged 6 \nmonths to 4 \nyears. \n\nIn accordance \nwith the summary \nof product \ncharacteristics and \nthe relevant \nrecommendations \nor guidelines \nissued by the \nNational \nImmunisation \nAdvisory \nCommittee and \naccepted by the \nMinister for \nHealth. \n\nAny suitable \nand appropriate \nplace, having \nregard to public \nconvenience \nand the need to \nprotect the \nhealth and \nsafety of the \npublic and \nsafely \nadminister the \nproduct. \n\n \n \n \n \n \n \n \n \n \n \n \n \n\f4 [582] \n\nNuvaxovid JN.1 \ndispersion for \ninjection \n\nCOVID-19 \nVaccine \n(recombinant, \nadjuvanted) \n\n”. \n\nDispersion for \ninjection \n\nIntramuscular \ninjection \n\nIndicated \nfor active \nimmunisati\non to \nprevent \nCOVID-19 \ncaused by \nSARSCoV-2 in \nindividuals \n12 years of \nage and \nolder \n\nIn accordance \nwith the summary \nof product \ncharacteristics and \nthe relevant \nrecommendations \nor guidelines \nissued by the \nNational \nImmunisation \nAdvisory \nCommittee and \naccepted by the \nMinister for \nHealth. \n\nAny suitable \nand appropriate \nplace, having \nregard to public \nconvenience \nand the need to \nprotect the \nhealth and \nsafety of the \npublic and \nsafely \nadminister the \nproduct. \n\nThe Twelfth Schedule (as amended by Regulation 8 of the 2024 Regulations) to \nthe Principal Regulations is amended by inserting the following entry: \n\n“ \n\nMedicinal \nproduct \n\nForm and \npresentation of \nproduct \nadministered \n\nRoute of \nadministration \n\nIndication for which \nthe medicinal product \nmay be administered \n\nDosage and conditions \nof administration \n\nColumn 1 \n\nColumn 2 \n\nColumn 3 \n\nColumn 4 \n\nColumn 5 \n\nDispersion for \ninjection \n\nIntramuscular \ninjection \n\nDispersion for \ninjection \n\nIntramuscular \ninjection \n\nConcentrate for \ndispersion for \ninjection \n\nIntramuscular \ninjection \n\nComirnaty KP.2 \n30 \nmicrograms/dose \ndispersion for \ninjection COVID19 mRNA \nVaccine \n\nComirnaty KP.2 \n10 \nmicrograms/dose \ndispersion for \ninjection COVID19 mRNA \nVaccine \n\nComirnaty KP.2 \n3 \nmicrograms/dose \nconcentrate for \ndispersion \nCOVID-19 \nmRNA Vaccine \n\nIndicated for active \nimmunisation to \nprevent COVID-19 \ncaused by SARS-CoV2, in individuals 12 \nyears of age and older \n\nIndicated for active \nimmunisation to \nprevent COVID-19 \ncaused by SARS-CoV2, in children aged 5 to \n11 years. \n\nIndicated for active \nimmunisation to \nprevent COVID-19 \ncaused by SARS-CoV2, in infants and \nchildren aged 6 months \nto 4 years. \n\nIn accordance with the \nsummary of product \ncharacteristics and the \nrelevant \nrecommendations or \nguidelines issued by \nthe National \nImmunisation Advisory \nCommittee and \naccepted by the \nMinister for Health. \n\nIn accordance with the \nsummary of product \ncharacteristics and the \nrelevant \nrecommendations or \nguidelines issued by \nthe National \nImmunisation Advisory \nCommittee and \naccepted by the \nMinister for Health. \n\nIn accordance with the \nsummary of product \ncharacteristics and the \nrelevant \nrecommendations or \nguidelines issued by \nthe National \nImmunisation Advisory \nCommittee and \naccepted by the \nMinister for Health. \n\n \n \n \n \n \n \n \n\f[582] 5 \n\nMedicinal \nproduct \n\nForm and \npresentation of \nproduct \nadministered \n\nRoute of \nadministration \n\nIndication for which \nthe medicinal product \nmay be administered \n\nDosage and conditions \nof administration \n\nDispersion for \ninjection \n\nIntramuscular \ninjection \n\nIndicated for active \nimmunisation to \nprevent COVID-19 \ncaused by SARS-CoV2 in individuals 12 \nyears of age and older \n\nIn accordance with the \nsummary of product \ncharacteristics and the \nrelevant \nrecommendations or \nguidelines issued by \nthe National \nImmunisation Advisory \nCommittee and \naccepted by the \nMinister for Health. \n\nNuvaxovid JN.1 \ndispersion for \ninjection \n\nCOVID-19 \nVaccine \n(recombinant, \nadjuvanted) \n\n”. \n\nGIVEN under my Official Seal, \n\n30 October, 2024. \n\nSTEPHEN DONNELLY, \nMinister for Health. \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\f6 [582]", "text_norm": "3 regulation - principal regulation mean medicinal product (prescription control supply) regulation 2003 ( s.i no 540 2003) regulation 2024 mean medicinal product (prescription control supply) (no 4) regulation 2024 (s.i no 458 2024) eighth schedule (as amended regulation 7 2024 regulations) principal regulation amended inserting following entry notice making statutory instrument published iris oifigiuil 1st november 2024 582 3 medicinal product route administration form presentation product administered indication medicinal product may administer ed dosage condition administration place administration column 1 column 2 column 3 column 4 column 5 column 6 dispersion injection intramuscular injection comirnaty kp.2 30 microgram dose dispersion injection covid-19 mrna vaccine dispersion injection intramuscular injection comirnaty kp.2 10 microgram dose dispersion injection covid-19 mrna vaccine concentrate dispersion injection intramuscular injection comirnaty kp.23 microgram dose concentrate dispersion covid-19 mrna vaccine indicated active immunisati prevent covid-19 caused sarscov-2 individual 12 year age older indicated active immunisati prevent covid-19 caused sarscov-2 child aged 5 11 year accordance summary product characteristic relevant recommendation guideline issued national immunisation advisory committee accepted minister health suitable appropriate place regard public convenience need protect health safety public safely administer product accordance summary product characteristic relevant recommendation guideline issued national immunisation advisory committee accepted minister health suitable appropriate place regard public convenience need protect health safety public safely administer product indicated active immunisati prevent covid-19 caused sarscov-2 infant child aged 6 month 4 year accordance summary product characteristic relevant recommendation guideline issued national immunisation advisory committee accepted minister health suitable appropriate place regard public convenience need protect health safety public safely administer product 4 582 nuvaxovid jn.1 dispersion injection covid-19 vaccine (recombinant adjuvanted)  dispersion injection intramuscular injection indicated active immunisati prevent covid-19 caused sarscov-2 individual 12 year age older accordance summary product characteristic relevant recommendation guideline issued national immunisation advisory committee accepted minister health suitable appropriate place regard public convenience need protect health safety public safely administer product twelfth schedule (as amended regulation 8 2024 regulations) principal regulation amended inserting following entry medicinal product form presentation product administered route administration indication medicinal product may administered dosage condition administration column 1 column 2 column 3 column 4 column 5 dispersion injection intramuscular injection dispersion injection intramuscular injection concentrate dispersion injection intramuscular injection comirnaty kp.2 30 microgram dose dispersion injection covid19 mrna vaccine comirnaty kp.2 10 microgram dose dispersion injection covid19 mrna vaccine comirnaty kp.2 3 microgram dose concentrate dispersion covid-19 mrna vaccine indicated active immunisation prevent covid-19 caused sars-cov2 individual 12 year age older indicated active immunisation prevent covid-19 caused sars-cov2 child aged 5 11 year indicated active immunisation prevent covid-19 caused sars-cov2 infant child aged 6 month 4 year accordance summary product characteristic relevant recommendation guideline issued national immunisation advisory committee accepted minister health accordance summary product characteristic relevant recommendation guideline issued national immunisation advisory committee accepted minister health accordance summary product characteristic relevant recommendation guideline issued national immunisation advisory committee accepted minister health 582 5 medicinal product form presentation product administered route administration indication medicinal product may administered dosage condition administration dispersion injection intramuscular injection indicated active immunisation prevent covid-19 caused sars-cov2 individual 12 year age older accordance summary product characteristic relevant recommendation guideline issued national immunisation advisory committee accepted minister health nuvaxovid jn.1 dispersion injection covid-19 vaccine (recombinant adjuvanted)  given official seal 30 october 2024 stephen donnelly minister health 6 582", "start_char": 983, "end_char": 7370, "source_path": "downloads\\2024\\2024_0582.pdf", "extraction_method": "pdfminer", "checksum": "sha256:605b5ae642fcf12b88545bd011e9e8f0d8c15091776cc2676d2f3b077c2348ea", "cross_refs": []}
{"doc_id": "si-2024-0582-explanatory-note", "parent_doc_id": "si-2024-0582", "section_id": "explanatory-note", "section_label": "EXPLANATORY NOTE", "si_number": "S.I. No. 582 of 2024", "title": "“Principal Regulations” means the Medicinal Products (Prescription and Control", "year": 2024, "heading": "(This note is not part of the Instrument and does not purport to be a legal", "text_raw": "EXPLANATORY NOTE \n\n(This note is not part of the Instrument and does not purport to be a legal \ninterpretation.) \n\nThese Regulations amend the Medicinal Products (Prescription and Control of \nSupply) Regulations 2003. \n\nThe purpose of these Regulations is to update the schedules of medicinal \nproducts which may be supplied and administered pursuant to Regulation 4B \nand Regulation 4F of the Medicinal Products (Prescription and Control of \nSupply) Regulations 2003. \n\nThese Regulations may be cited as the Medicinal Products (Prescription and \nControl of Supply) (Amendment) (No. 5) Regulations 2024. \n\n \n \n \n \n \n \n \n\f[582] 7 \n\nBAILE ÁTHA CLIATH \nARNA FHOILSIÚ AG OIFIG AN tSOLÁTHAIR \nLe ceannach díreach ó \nFOILSEACHÁIN RIALTAIS, \nBÓTHAR BHAILE UÍ BHEOLÁIN, \nCILL MHAIGHNEANN, \nBAILE ÁTHA CLIATH 8, \nD08 XAO6 \n\nTeil: 046 942 3100 \nr-phost: publications@opw.ie \n—————— \n\nDUBLIN \nPUBLISHED BY THE STATIONERY OFFICE \nTo be purchased from \nGOVERNMENT PUBLICATIONS, \nMOUNTSHANNON ROAD, \nKILMAINHAM, DUBLIN 8, \nD08 XAO6 \n\nTel: 046 942 3100 \nE-mail: publications@opw.ie \n—————— \n\n€ 3.00 \n\n(DH-552) 30. 11/24. Propylon.", "text_norm": "explanatory note (this note part instrument purport legal interpretation.) regulation amend medicinal product (prescription control supply) regulation 2003 purpose regulation update schedule medicinal product may supplied administered pursuant regulation 4b regulation 4f medicinal product (prescription control supply) regulation 2003 regulation may cited medicinal product (prescription control supply) (amendment) (no 5) regulation 2024 582 7 baile atha cliath arna fhoilsiu ag oifig tsolathair le ceannach direach foilseachain rialtais bothar bhaile ui bheolain cill mhaighneann baile atha cliath 8 d08 xao6 teil 046 942 3100 r-phost publication opw.ie ------------ dublin published stationery office purchased government publication mountshannon road kilmainham dublin 8 d08 xao6 tel 046 942 3100 e-mail publication opw.ie ------------ eur 3.00 (dh-552) 30 11 24 propylon", "start_char": 7370, "end_char": 8485, "source_path": "downloads\\2024\\2024_0582.pdf", "extraction_method": "pdfminer", "checksum": "sha256:605b5ae642fcf12b88545bd011e9e8f0d8c15091776cc2676d2f3b077c2348ea", "cross_refs": []}
